GHK-Cu Injection vs Topical: Absorption, Results, Risks

Key takeaways

• Topical GHK-Cu has about thirty years of small human studies: modest improvement in fine lines, firmness and thickness after 8 to 12 weeks, one positive and one negative wound trial, one negative post-laser trial, one 18-person eyebrow study. Injected GHK-Cu has none: no efficacy, safety, dosing or pharmacokinetic study in people.
• No US pharmacy may compound injectable GHK-Cu as of October 2026. It sat on FDA's Category 2 safety-risk list from September 2023, came off on April 15, 2026 only because its nomination was withdrawn, and waits for an advisory committee review due by February 2027. Every 'GHK-Cu injection' for sale is a research vial.
• The argument for injecting is absorption: copper peptide does not cross intact skin well. The lab data are mixed (a 48-hour experiment pushed copper through excised skin; a 9-hour one found almost none crossed), and the argument proves nothing about benefit. Better delivery of an unproven effect is still unproven.
• Injected copper skips the gut, the organ that limits copper uptake. A 2 mg shot carries about 0.3 mg of elemental copper; a 50 mg vial about 8 mg. What that does to the liver over weeks has never been measured, and one clinician told NPR he has seen self-injectors with raised liver enzymes and copper levels.
• If you want copper peptide, the cream is the version with data. If you want results, a retinoid and sunscreen have far more. If you have been injecting, stop and ask a clinician to check liver enzymes and copper.

GHK-Cu injection versus topical has a short answer: the cream has small human studies and the needle has none. Topical copper peptide has modest reported improvements in fine lines, firmness and thickness in 12-week studies, plus mixed results in wounds. Injected GHK-Cu has no human study of any kind, cannot be compounded by any US pharmacy, and delivers copper past the gut's controls. This page compares the two routes on absorption, evidence, legality, risk and cost. Our best peptides for skin guide ranks copper peptide against retinoids and the other cosmetic peptides, GHK-Cu results by week covers what the topical studies measured and when, and the GHK-Cu profile has the full evidence table, the dosing history and the legal timeline.

Why anyone injects a cream ingredient

GHK-Cu spent three decades as a cosmetic before social media moved it into syringes, usually inside a GLOW or KLOW blend with BPC-157 and TB-500. Two arguments drive the move. The first is absorption: the peptide does not cross intact skin easily, and a needle puts all of it into tissue; a cosmetic dermatologist made that observation to NPR in September 2026 and in the same breath told patients to hold off until human studies exist (NPR 2026). The second is the inventor's claim that blood GHK falls with age and should be replaced, a figure never independently measured and never tested by a replacement trial, as the profile explains. Both arguments are about delivery. Neither is about results, because there are none.

Injection versus topical: the comparison

What is actually known about absorption

Through the skin. Two laboratories have measured copper peptide crossing excised human skin, and they disagree. At the University of California, San Francisco, a 0.68 percent GHK-Cu solution kept on the skin for 48 hours under infinite-dose conditions pushed about 136 micrograms of copper per square centimeter through dermatomed (split-thickness) skin and left roughly 97 micrograms behind as a depot, amounts the authors considered potentially useful for delivering copper as an anti-inflammatory (Hostynek 2011). In Singapore, almost no peptide or copper crossed intact human skin in 9 hours until the skin was pierced with a microneedle array (Li 2015). Neither experiment resembles a dab of serum worn for a day; the 2026 evidence map notes that even the eyebrow trial did not define what form of the complex reached the skin or how much (Mateescu 2026); and we found no study, in PubMed as of October 10, 2026, measuring GHK-Cu or copper in a person's blood after a topical product. For a cosmetic, limited penetration is not a flaw: the 12-week studies measured changes in the skin the cream was applied to, which needs no systemic exposure, and it keeps the copper where the body sheds it with the outer skin.

By injection. Absorption is total by definition; what matters is what happens next, and nothing has been measured: not blood levels, not how long the complex holds its copper, not where the copper ends up, not what repeated doses do to the liver. The 2026 review lists what an injectable copper peptide would have to characterize first (sterility, endotoxin, particles, aggregation, loose copper, route-specific safety thresholds) and finds none of it done (Mateescu 2026).

The copper arithmetic. GHK-Cu is about 16 percent copper by weight, so a 2 mg injection carries roughly 0.3 mg of elemental copper and a 50 mg vial about 8 mg. The body keeps copper in range mainly by limiting absorption in the gut and excreting the surplus in bile; balance studies find net loss at dietary intakes below about 0.8 mg a day and net gain above about 2.4 mg a day (Bost 2016). Those figures describe copper that has passed through the gut's gate; an injection skips it, which is why oral safety limits cannot be converted into injection limits. None of this proves that 0.3 mg a day under the skin is harmful. It shows that nobody has checked.

The seller claims, presented as claims

The reconstitution math is the one honest line in these charts; our peptide calculator will do it for any vial, and it tells you how many units to draw of a solution whose content, sterility and effect are all unverified.

Risks: topical versus injected

Topical. The documented problems are stinging or redness, usually from the vehicle or from layering copper peptide with strong acids or high-dose vitamin C in the same step, and allergic contact dermatitis in people sensitized to copper, a known risk of any copper-containing product (Mateescu 2026). Stop if a rash spreads beyond where the product went on. There is no evidence of systemic effects from cosmetic use.

Injected. Three layers of risk, none quantified. The first is generic to research vials: injection-site infection, fever and shock from endotoxin, wrong doses from mislabeled content, and immune reactions to peptide impurities and aggregates, the concern FDA cited when it placed injectable GHK-Cu in Category 2 in 2023 (FDA Category 2). The second is copper, as above. The third is what happens when no pharmacist or clinician is in the chain: the Seattle-area clinician in NPR's report described self-injectors with injection-site irritation, infections, and raised liver enzymes and copper levels after injecting too much, while allowing that he could not tell whether the peptide, an impurity or something else in the vial was responsible (NPR 2026). That is an anecdote, which is what every safety signal looks like when nobody is counting.

The first layer has a documented example in a sister compound. The one published case report we found of a cosmetic peptide injected into the face involved Argireline, not GHK-Cu: a 45-year-old woman developed nodules and abscesses at the forehead and temple injection sites within a week, cultures grew Mycobacterium abscessus, and she needed five months of two antibiotics (Chen 2021). Nothing about GHK-Cu makes it immune to the same failure. Anyone with Wilson disease or another copper disorder, chronic liver disease, a copper or metal allergy, a current or recent cancer, or a pregnancy should not inject GHK-Cu under any circumstances; the profile explains each.

What to do instead

1. Use the topical the way it was studied. Retail serums list copper tripeptide-1 at 0.5 to 3 percent; apply once or twice daily for 8 to 12 weeks after a patch test, at a different time of day from strong acids. GHK-Cu results by week sets realistic expectations.
2. Spend the injection money on grade A evidence. Daily sunscreen and a prescription retinoid outperform every peptide in the skin guide.
3. Ask the pharmacy question. If a clinic offers GHK-Cu injections, ask which pharmacy fills them and on what 503A basis. There is no legal answer as of October 2026, as the legal tracker explains; removal from Category 2 in April 2026 did not make the substance eligible for compounding (Frier Levitt 2026), and the committee review due by February 2027 may change what pharmacies can do but will not create the human data.
4. If you have already been injecting, stop and get checked. Liver enzymes and a copper level are reasonable tests to ask a clinician for; bring the vial so the clinician knows, as far as anyone can, what was in it.

Bottom line

Topical GHK-Cu is a cosmetic with small studies, a long safety record and modest effects. Injectable GHK-Cu is the same molecule with no studies, no safety data, no legal source and a copper load the body was built to screen at the gut, not the needle. The absorption argument for injecting is correct and irrelevant: delivering more of an effect that has only been shown in the skin it touched is not evidence that the effect exists anywhere else. Use the cream if you like it, and wait for the trial before anyone puts it in a syringe.

Frequently asked questions

+−Is GHK-Cu injection safe?

Nobody knows, because no human study of injected GHK-Cu on its own exists: no safety trial, no dosing study, no measurement of where the copper goes. The nameable concerns are the ones that apply to any research vial (sterility, endotoxin, wrong content, immune reactions to impurities, which is the reason FDA gave for flagging it in 2023) plus one specific to this molecule: copper delivered past the gut, which normally limits how much gets in. A clinician told NPR in September 2026 that he has seen self-injectors with raised liver enzymes and copper levels. Topical GHK-Cu, by contrast, has decades of cosmetic use with irritation and copper contact allergy as the documented problems.

+−What is the GHK-Cu injection dosage?

There is no studied dose, because there is no human study. The charts online (1 to 2 mg under the skin once a day, five days a week, for 4 to 8 weeks; 2 to 5 mg two or three times a week; 'start at 0.2 mg and titrate') are seller and influencer conventions extrapolated from rodent work and from the size of the vials. The only part of them that can be checked is the arithmetic: a 2 mg dose carries about 0.3 mg of elemental copper. The topical doses with data are creams and serums at 0.1 to 2 percent once or twice daily for 8 to 12 weeks.

+−Does injected GHK-Cu work better than topical?

No study has compared them, and no study has tested the injection at all. The argument for injecting is absorption: copper peptide does not cross intact skin well, so a needle must deliver more. That is true by definition and proves nothing about benefit, because the effect being delivered has only been shown, modestly, in the skin it was applied to. Better delivery of an unproven systemic effect is still unproven. A cosmetic dermatologist made the same point to NPR in 2026: the topical science is reasonable, and patients should wait for human studies before injecting.

+−Where can you get copper peptide injections?

Nowhere legitimate. No US pharmacy may compound injectable GHK-Cu as of October 2026, and there is no approved product anywhere. What exists are vials labeled for research use, synthesized in bulk and resold online, which FDA has said become unapproved drugs the moment the seller's website explains how to dose and inject them; the agency sent warning letters to five vendors on that basis in August 2026. A clinic or telehealth program listing GHK-Cu injections is handing you a research vial. We do not name or link to sellers.

+−What are the benefits of GHK-Cu injections?

None has been demonstrated. The benefits in the marketing (tighter skin, hair regrowth, faster healing, less inflammation, longevity) are extrapolated from cell cultures, rats, and small topical studies in which a cream improved fine lines and firmness over 12 weeks. The 2026 independent evidence map lists only topical human studies, and a 2026 sports-medicine primer found no clinical data for injected GHK-Cu in musculoskeletal conditions. Until a trial is run, the benefit of a GHK-Cu injection is a hypothesis.

+−Do copper peptides absorb through the skin?

Partly, and the laboratory data disagree about how much. In one set of experiments on excised human skin, a 0.68 percent copper peptide solution left on the skin for 48 hours delivered measurable copper through and into the tissue; in another, almost no peptide or copper crossed intact human skin in 9 hours unless the skin had first been pierced with microneedles. No study has measured GHK-Cu or copper in anyone's blood after using a cream. For a cosmetic that is not a problem: the small studies measured changes in the skin the product was applied to, which does not require the peptide to reach the bloodstream.

+−Are GHK-Cu injections legal?

Possessing a vial is not a crime; selling one for human use is selling an unapproved drug. Injectable GHK-Cu was placed on FDA's Category 2 safety-risk list in September 2023, removed on April 15, 2026 only because its nomination was withdrawn, and is scheduled for advisory committee review before the end of February 2027. Removal from Category 2 does not make a substance compoundable, so as of October 2026 no 503A pharmacy may prepare it. Topical GHK-Cu is legal as a cosmetic without drug claims. Our legal tracker updates when FDA acts.

Sources

1. ReviewMateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap (systematic evidence-mapping review). Pharmaceutics 2026;18:1077. (2026)
2. StudyHostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res 2011;60:79-86. (2011)
3. StudyLi H et al. Microneedle-mediated delivery of copper peptide through skin. Pharm Res 2015;32:2678-89. (2015)
4. ReviewBost M et al. Dietary copper and human health: current evidence and unresolved issues. J Trace Elem Med Biol 2016;35:107-15. (2016)
5. StudyChen CF et al. Mycobacterium abscessus infection after facial injection of argireline: a case report. World J Clin Cases 2021;9:1996-2000. (2021)
6. NewsStone W. The copper peptide trend has gone from creams to injections, ahead of the science. NPR, September 7, 2026 (republished by WUNC). (2026)
7. RegulatoryFDA. Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list; injectable GHK-Cu listed September 2023, citing immunogenicity concerns).
8. NewsFrier Levitt. FDA to remove 12 popular peptides from the Category 2 'do not compound' list (injectable GHK-Cu removed from Category 2 and non-injectable GHK-Cu from Category 1; removal does not make them eligible for compounding; committee review due before the end of February 2027). April 16, 2026. (2026)
9. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)